No Data
No Data
Rendo Biotech (688193.SH): Repurchased 3.1288% of shares.
On July 24th, Gelunhui reported that Rendu Biology (688193.SH) has announced that as of July 24th, 2024, the company has repurchased a total of 1,251,539 shares of the company through the Shanghai Stock Exchange trading system using centralized bidding trading method, accounting for 3.1288% of the company's total share capital of 40,000,000 shares. The highest price of the repurchase transaction was 30.55 yuan/share and the lowest price was 24.44 yuan/share. The total amount paid, excluding transaction fees such as stamp duty and transaction commission, was RMB 34,656,300.25.
Rendo Biotech (688193.SH): The company and relevant parties received criticism from the Shanghai Stock Exchange.
RenDu Bio (688193.SH) announced that on July 12th, 2024 the company received a letter from the Shanghai Stock Exchange (...)
For the year 2023, Ren Du Bioscience (688193.SH) will distribute 2 yuan per 10 shares, with a record date of June 26th.
RenDu Biotech (688193.SH) announced that the company will implement the annual equity distribution for the year 2023, distributing a cash dividend of 2 yuan (tax included) for every 10 shares. The record date for the equity is June 26.
There Are Some Holes In Shanghai Rendu Biotechnology's (SHSE:688193) Solid Earnings Release
Rendu Biotech (688193.SH): cumulative repurchase of 2.0104% of the company's shares
Gelonghui, May 6, 丨 Rendu Biotech (688193.SH) announced that as of April 30, 2024, the company had repurchased 804,169 shares of the company through centralized bidding transactions, accounting for 2.0104% of the company's total share capital. The highest price of the repurchase transaction was 30.55 yuan/share, the lowest price was 26.31 yuan/share, and the total amount of capital paid was RMB 23,371,319.49 (excluding transaction fees such as stamp duty and transaction fees).
Rendu Biotech (688193.SH): Net profit of 3.7039 million yuan in the first quarter
On April 29, Ge Longhui (688193.SH) released its report for the first quarter of 2024, achieving operating income of 44.8151 million yuan, an increase of 15.60% over the previous year; net profit attributable to shareholders of listed companies was 3.7039 million yuan, and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1.0853 million yuan, with basic earnings per share of 0.09 yuan.
No Data